|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1211 Medical Center Drive |
Address2 | Suite D-3300 MCN |
City | Nashville |
State | TN |
Zip Code | 37232 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401104096-12
|
||||||||
|
6. House ID# 433060001
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: John Manning |
Date | 7/20/2020 12:41:28 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R.7308, the Research Investment to Spark the Economy Act or the RISE Act, provisions related to NIH research relief funding.
Issues related to supplemental, emergency funding for public health, research and health care delivery needs resulting from the COVID-19 pandemic.
Issues related to FY 21 funding for NIH.
Issues related to FY 21 funding for CDC.
Issues related to FY 21 funding for HRSA.
Issues related to FY 21 funding for VA Medical Research.
Issues related to FY21 funding for AHRQ.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexander |
Currie |
|
Senior Director of VUMC Federal Relations |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020, issues related to telehealth flexibilities, public health funding.
H.R.6201, Families First Coronavirus Response Act, health provisions.
H.R.748, the Coronavirus Aid, Relief, and Economic Security Act or the CARES Act, issues related to support for patients, healthcare workers and providers.
H.R.6800, the HEROES Act, provisions related to health care providers.
S.3993, Equal Access to Care Act, provisions related to telehealth.
S.2408/H.R.4900, Telehealth Across State Lines Act
xx, the TREAT Act, provisions related to state licensure reciprocity during a Public Health Emergency
S.1895, the Lower Health Care Cost Act, issues related to surprise billing, air ambulance, provider-payor contracting, among others.
S.3404/H.R.6102, the VALID Act, issues related to the regulation of in vitro diagnostic tests.
Issues related to funding for and allocations from the CARES ACT Provider Relief Fund.
Issues related to access to PPE and testing supplies.
Issues related to the extension of the COVID Public Health Emergency.
Issues related to the creation of hospital surge capacity to address the COVID19 pandemic.
Issues related to federal support for hospitals experiencing revenue loss from canceled elective procedures/clinic visits.
Issues related to state licensure reciprocity and related federal policies as they impact the provision of telehealth services across state lines.
Issues around coverage for the uninsured needing COVID-19 care and technical issues with HRSA data collection on uninsured care.
Issues related to protecting insurance coverage, including through subsidies for COBRA coverage.
Issues related to national preparedness for future pandemic threats.
Issues related to Organ Procurement Organization performance metrics.
Issues related to HRSA Addiction Medicine Fellowship program.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexander |
Currie |
|
Senior Director of VUMC Federal Relations |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020, issues related to supplemental research and public health funding related to COVID-19.
H.R.748, the Coronavirus Aid, Relief, and Economic Security Act or the CARES Act, issues related to additional research funding.
H.R.6800, the HEROES Act, provisions related to research funding.
H.R.7308, the Research Investment to Spark the Economy Act or the RISE Act, provisions related to NIH research relief funding.
Issues related to FY 21 funding for NIH.
Issues related to FY 21 funding for VA Medical Research.
Issues related to funding the All of Us research program.
Issues related to funding of the CTSA program at NCATS/NIH.
Issues related to funding for the NIH HEAL Initiative.
Issues related to the RADx Initiative.
Issues related to Operation Warp Speed.
Issues related to COVID-19 research funding.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexander |
Currie |
|
Senior Director of VUMC Federal Relations |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Implementation of the CARES Act Provider Relief Fund.
Concerns with the Medicare Fiscal Accountability proposed Rule (MFAR).
Issues related to delay of Medicaid DSH reductions.
Issues related to CMS policies on telehealth services in response to COVID-19.
Issues related to accelerated and advanced payments to provide providers with financial liquidity during the COVID-19 pandemic.
Issues related to MAC assignments.
Issues around Medicare reimbursement for CAR-T therapy.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexander |
Currie |
|
Senior Director of VUMC Federal Relations |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Issues related to funding for VA Medical Research.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexander |
Currie |
|
Senior Director of VUMC Federal Relations |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Issues related to temporary COBRA subsidies or other means to protect employer sponsored coverage.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexander |
Currie |
|
Senior Director of VUMC Federal Relations |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Issues related to DIR fees.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexander |
Currie |
|
Senior Director of VUMC Federal Relations |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |